Literature DB >> 26471955

VT Recurrence After Ablation: Incomplete Ablation or Disease Progression? A Multicentric European Study.

B Berte1, F Sacher1, J Venlet2, D Andreu3, S Mahida1, B Aldhoon4, T DE Potter5, A Sarkozy6, R Tavernier7, M Andronache8, T Deneke9, J Kautzner4, A Berruezo3, H Cochet1, K Zeppenfeld2, Pierre Jaïs1.   

Abstract

AIM: To determine whether ventricular tachycardia (VT) recurrences in arrhythmogenic RV cardiomyopathy (ARVC) and nonischemic cardiomyopathy (NICM) are related to incomplete ablation or disease progression.
METHODS: ARVC and NICM patients with two substrate maps of the same diseased ventricle with an interprocedural delay of ≥12 months were included. Disease progression was defined as ≥1 factor: scar area progression (PROG, +5%), ventricular remodeling (dilatation [+25 mL] or decreased ejection fraction [-5%EF]). Incomplete ablation was defined as index VT recurrence or ablation in previously unablated regions inside index scar without PROG.
RESULTS: Twenty patients from nine centers were included (80% male 55 ± 16 years, 7 ARVC and 13 NICM, LVEF 43 ± 14%). Mean delay was 28 ± 18 months. Disease progression occurred in 75% with ventricular remodeling in 70%: ventricular dilation in 45% (ARVC [71%]; NICM [38%]), decreased EF in 60% [RVEF in ARVC (71%); LVEF in NICM (54%)], and scar progression in 50% (in ARVC [57%] and NICM [46%]). Index VT recurrence was observed in 40%. Redo ablation sites were located in previously unablated regions inside the index scar in 70% of patients. VT recurrence following the second procedure was seen in 25%. Fifteen percent died during a follow-up of 17 ± 17 months.
CONCLUSION: Disease progression is the rule in ARVC and NICM while scar progression occurs in half. However, even if disease progression is frequently observed, incomplete index ablation is the most common finding, strongly suggesting the need for more extensive ablation.
© 2015 Wiley Periodicals, Inc.

Entities:  

Keywords:  arrhythmogenic right ventricular cardiomyopathy; catheter ablation; nonischemic cardiomyopathy; substrate map; ventricular tachycardia

Mesh:

Year:  2015        PMID: 26471955     DOI: 10.1111/jce.12858

Source DB:  PubMed          Journal:  J Cardiovasc Electrophysiol        ISSN: 1045-3873


  9 in total

1.  Recurrent ventricular tachycardia after cardiac sympathetic denervation: Prolonged cycle length with improved hemodynamic tolerance and ablation outcomes.

Authors:  Justin Hayase; Veronica Dusi; Duc Do; Olujimi A Ajijola; Marmar Vaseghi; Jay M Lee; Jane Yanagawa; Nir Hoftman; Sha'Shonda Revels; Eric F Buch; Houman Khakpour; Osamu Fujimura; Yuliya Krokhaleva; Carlos Macias; Julie Sorg; Jean Gima; Geraldine Pavez; Noel G Boyle; Kalyanam Shivkumar; Jason S Bradfield
Journal:  J Cardiovasc Electrophysiol       Date:  2020-06-30

2.  2019 HRS/EHRA/APHRS/LAHRS expert consensus statement on catheter ablation of ventricular arrhythmias.

Authors:  Edmond M Cronin; Frank M Bogun; Philippe Maury; Petr Peichl; Minglong Chen; Narayanan Namboodiri; Luis Aguinaga; Luiz Roberto Leite; Sana M Al-Khatib; Elad Anter; Antonio Berruezo; David J Callans; Mina K Chung; Phillip Cuculich; Andre d'Avila; Barbara J Deal; Paolo Della Bella; Thomas Deneke; Timm-Michael Dickfeld; Claudio Hadid; Haris M Haqqani; G Neal Kay; Rakesh Latchamsetty; Francis Marchlinski; John M Miller; Akihiko Nogami; Akash R Patel; Rajeev Kumar Pathak; Luis C Saenz Morales; Pasquale Santangeli; John L Sapp; Andrea Sarkozy; Kyoko Soejima; William G Stevenson; Usha B Tedrow; Wendy S Tzou; Niraj Varma; Katja Zeppenfeld
Journal:  J Interv Card Electrophysiol       Date:  2020-10       Impact factor: 1.900

3.  2019 HRS/EHRA/APHRS/LAHRS expert consensus statement on catheter ablation of ventricular arrhythmias.

Authors:  Edmond M Cronin; Frank M Bogun; Philippe Maury; Petr Peichl; Minglong Chen; Narayanan Namboodiri; Luis Aguinaga; Luiz Roberto Leite; Sana M Al-Khatib; Elad Anter; Antonio Berruezo; David J Callans; Mina K Chung; Phillip Cuculich; Andre d'Avila; Barbara J Deal; Paolo Della Bella; Thomas Deneke; Timm-Michael Dickfeld; Claudio Hadid; Haris M Haqqani; G Neal Kay; Rakesh Latchamsetty; Francis Marchlinski; John M Miller; Akihiko Nogami; Akash R Patel; Rajeev Kumar Pathak; Luis C Sáenz Morales; Pasquale Santangeli; John L Sapp; Andrea Sarkozy; Kyoko Soejima; William G Stevenson; Usha B Tedrow; Wendy S Tzou; Niraj Varma; Katja Zeppenfeld
Journal:  Europace       Date:  2019-08-01       Impact factor: 5.214

Review 4.  Optimal Ablation Techniques for Ventricular Tachycardia Management.

Authors:  Jose M Sanchez; Chen Yuan; Henry H Hsia
Journal:  J Innov Card Rhythm Manag       Date:  2018-01-15

5.  Catheter Ablation of Ventricular Tachycardia in Patients With Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia: A Sequential Approach.

Authors:  Shibu Mathew; Ardan M Saguner; Niklas Schenker; Lukas Kaiser; Pengpai Zhang; Yoshiga Yashuiro; Christine Lemes; Thomas Fink; Tilman Maurer; Francesco Santoro; Peter Wohlmuth; Bruno Reißmann; Christian H Heeger; Roland Tilz; Erik Wissner; Andreas Rillig; Andreas Metzner; Karl-Heinz Kuck; Feifan Ouyang
Journal:  J Am Heart Assoc       Date:  2019-03-05       Impact factor: 5.501

6.  Ablation strategies for arrhythmogenic right ventricular cardiomyopathy: a systematic review and meta-analysis.

Authors:  Li-Shui Shen; Li-Min Liu; Li-Hui Zheng; Feng Hu; Zhi-Cheng Hu; Shang-Yu Liu; Jin-Rui Guo; Kush Kumar Bhagat; Yan Yao
Journal:  J Geriatr Cardiol       Date:  2020-11-28       Impact factor: 3.327

7.  Catheter ablation of scar based ventricular tachycardia - Procedural characteristics and outcomes.

Authors:  Ashutosh Yadav; Sakthivel Ramasamy; Joseph Theodore; Avinash Anantharaj; Ajith Ananthakrishna Pillai; Santhosh Satheesh; Raja J Selvaraj
Journal:  Indian Heart J       Date:  2020-09-19

Review 8.  Cardiac Magnetic Resonance for Ventricular Tachycardia Ablation and Risk Stratification.

Authors:  Ivo Roca-Luque; Lluis Mont-Girbau
Journal:  Front Cardiovasc Med       Date:  2022-01-12

9.  Cycle length of nonsustanied ventricular tachycardias among ICD patients: implications on subsequent appropriate therapies.

Authors:  Javier Jiménez-Candil; Olga Duran; Armando Oterino; Jendri Pérez; Juan Carlos Castro; Jesús Hernández; José Moríñigo; Manuel Sánchez García; Pedro L Sánchez
Journal:  BMC Cardiovasc Disord       Date:  2021-05-31       Impact factor: 2.298

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.